Data updated: Mar 29, 2026

ORYZA

Infectious Disease

Generics

ORYZA is a generic drug manufacturer focused on Infectious Disease.

2020

Since

2

Drugs

-

Trials

102

Approved (2yr)

Key Drugs

No active drugs

Top Drug Revenues ProEarly access

Loading...

Revenue Over Time ProEarly access

Loading...

Recent Activity

DOXYCYCLINE HYCLATE 2026-02-19

DOXYCYCLINE HYCLATE 2026-02-06

DOXYCYCLINE HYCLATE 2026-02-06

DOXYCYCLINE HYCLATE 2026-01-26

DOXYCYCLINE HYCLATE 2026-01-20

DOXYCYCLINE HYCLATE 2026-01-20

DOXYCYCLINE HYCLATE 2026-01-18

DOXYCYCLINE HYCLATE 2025-12-09

SEC Filings ProEarly access

Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Infectious Disease 100%

1 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones ProEarly access

Loading...

Patent Cliff ProEarly access

Loading...

Competitors by Therapeutic Area

Pfizer big-pharma

Infectious Disease

Merck big-pharma

Infectious Disease

Baxter specialty

Infectious Disease

AbbVie big-pharma

Infectious Disease

Johnson & Johnson big-pharma

Infectious Disease